Condition: Non Small Cell Lung Cancer · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 768 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham - Main /ID# 247074 | Birmingham, Alabama, United States | Active Not Recruiting |
| Ironwood Cancer & Res Ctr /ID# 262446 | Chandler, Arizona, United States | Active Not Recruiting |
| Mayo Clinic Arizona /ID# 255858 | Phoenix, Arizona, United States | Active Not Recruiting |
| Onvida Health Yuma Medical Center /ID# 253625 | Yuma, Arizona, United States | Completed |
| City of Hope /ID# 243157 | Duarte, California, United States | Recruiting |
| City Of Hope - Seacliff /ID# 263143 | Huntington Beach, California, United States | Recruiting |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144 | Irvine, California, United States | Recruiting |
| City Of Hope - Antelope Valley /ID# 263138 | Lancaster, California, United States | Recruiting |
| The Oncology Institute Of Hope & Innovation -East Los A /ID# 239774 | Los Angeles, California, United States | Completed |
| Eisenhower Medical Center /ID# 233189 | Rancho Mirage, California, United States | Completed |
| Premiere Oncology Foundation /ID# 253954 | Santa Monica, California, United States | Completed |
| Mayo Clinic Hospital Jacksonville /ID# 254688 | Jacksonville, Florida, United States | Completed |
+ 305 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04928846